Ann Surg Treat Res.  2018 Nov;95(5):267-277. 10.4174/astr.2018.95.5.267.

Clinical outcome of 1,000 consecutive cases of liver transplantation: a single center experience

• Kwak BJ
• Kim DG
• Han JH
• Choi HJ
• Bae SH
• You YK
• Choi JY
• Yoon SK

• KMID: 2422936
• DOI: http://doi.org/10.4174/astr.2018.95.5.267

Abstract

PURPOSE
The aim of this study was to analyze survival outcomes in 1,000 consecutive liver transplantations (LTs) performed at a single institution from 1993 to April 2017.
METHODS
The study population was divided into 2 groups based on donor type: deceased donor LT (DDLT; n = 181, 18.1%) and living donor LT (LDLT; n = 819; 81.9%), and into 3 periods based on the number of cases (first 300 cases, middle 300 cases, last 400 cases).
RESULTS
Infection was the most common cause of death, accounting for 34.8% (95 of 273). Mortality due to hepatocellular carcinoma recurrence occurred most frequently between 1 and 5 years after transplantation. Mortality rate by graft rejection was highest between 5 and 10 years after transplantation. And mortality by de novo malignancy occurred most frequently after 10 years after transplantation. The patient survival rates for the entire population at 5 and 10 years were 74.7%, and 68.6%, respectively. There was no difference in survival rate between the LDLT and DDLT groups (P = 0.188). Cause of disease, disease severity, case period, and retransplantation had a significant association with patient survival (P = 0.002, P = 0.031, P = 0.003, and P = 0.024, respectively).
CONCLUSION
Surgical techniques and perioperative management for transplant patients have improved and undergone standardization. Controlling perioperative infection and managing patients with HCC as LT candidates will result in better outcomes.

Keyword

Liver transplantation; Cause of death; Survival; Risk factors

MeSH Terms

Carcinoma, Hepatocellular
Cause of Death
Graft Rejection
Humans
Liver Transplantation*
Liver*
Living Donors
Mortality
Recurrence
Risk Factors
Survival Rate
Tissue Donors

Figure

• 

  Fig. 1 Overall survival analysis of 1,000 liver transplantations; overall survival in all cases (A), overall survival according to graft type (B) and overall survival in patients with hepatocellular carcinoma according to Milan criteria (C). LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation.

• 

  Fig. 2 Overall survival analysis of the 1,000 liver transplantations (LTs); causes of diseases (A), disease severity (B), case period (C), and primary versus retransplantation (D). Period 1: from June 1993 to May 2006; period 2: from May 2006 to April 2011; period 3: from April 2011 to April 2017.

Reference

1. Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, Moon JB, et al. Orthotopic homotransplantation of the human liver. Ann Surg. 1968; 168:392–415.

2. Lee KU, Kim SB, Kim SH, Lee HJ, Suh KS, Kim ST. Liver transplantation in Seoul National University Hospital. Transplant Proc. 2002; 34:2799–2800.

3. Strong RW, Lynch SV, Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver transplantation from a living donor to her son. N Engl J Med. 1990; 322:1505–1507.

4. Iwatsuki S, Shaw BW, Starzl TE. Fiveyear survival after liver transplantation. Transplant Proc. 1985; 17:259–263.

5. Berg CL, Steffick DE, Edwards EB, Heimbach JK, Magee JC, Washburn WK, et al. Liver and intestine transplantation in the United States 1998-2007. Am J Transplant. 2009; 9(4 Pt 2):907–931.

6. Yi NJ, Suh KS, Suh SW, Chang YR, Hong G, Yoo T, et al. Excellent outcome in 238 consecutive living donor liver transplantations using the right liver graft in a large volume single center. World J Surg. 2013; 37:1419–1429.

7. Tzakis A, Todo S, Starzl TE. Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg. 1989; 210:649–652.

8. Korea Centers for Disease Control & Prevention. 2016 Konos Annual Report [Internet]. Seoul (Korea): Korea Centers for Disease Control & Prevention, Korean Network for Organ Sharing;c2014. cited 2017 Sep 10. Available from: https://www.konos.go.kr/konosis/index.jsp.

9. Salizzoni M, Cerutti E, Romagnoli R, Lupo F, Franchello A, Zamboni F, et al. The first one thousand liver transplants in Turin: a single-center experience in Italy. Transpl Int. 2005; 18:1328–1335.

10. Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. Am J Transplant. 2015; 15:17–38.

11. Polak WG, Peeters PM, Slooff MJ. The evolution of surgical techniques in clinical liver transplantation. A review. Clin Transplant. 2009; 23:546–564.

12. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg. 2000; 232:490–500.

13. Schoening WN, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, et al. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transplant. 2013; 13:2384–2394.

14. Lee JS, Lee SH, Kim KS, Gil EM, Choi GS, Kim JM, et al. Bacterial infection monitoring in the early period after liver transplantation. Ann Surg Treat Res. 2018; 94:154–158.

15. Chan SC, Cheung TT, Chan AC, Chok KS, Sharr WW, Fung JY, et al. New insights after the first 1000 liver transplantations at The University of Hong Kong. Asian J Surg. 2016; 39:202–210.

16. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998; 28:585–589.

17. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334:693–699.

18. Tamura S, Sugawara Y, Kokudo N. Section 4. Further expanding the criteria for HCC in living donor liver transplantation: the Tokyo University experience. Transplantation. 2014; 97:Suppl 8. S17–S20.

19. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008; 8:1982–1989.

20. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33:1394–1403.

21. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim J, Durand F, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl. 2006; 12:1761–1769.

22. Todo S, Furukawa H. Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004; 240:451–459.

23. Freeman RB, Harper A, Edwards EB. Excellent liver transplant survival rates under the MELD/PELD system. Transplant Proc. 2005; 37:585–588.

24. Rana A, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant. 2008; 8:2537–2546.

25. Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl. 2006; 12:1049–1061.